APPLICATION OF MIR-31-5P IN ACUTE MYELOID LEUKEMIA

• Main Authors: ZHONG, Wenbin, YAN, Daoguang
• Format: Patent
• Language: Chinese; English; French
• Published: 12.01.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present disclosure relates to an application of miR-31-5p in acute myeloid leukemia (AML), particularly, a use of a product for detecting the miR-31-5p in preparation of a reagent, chip, or reagent kit for auxiliary diagnosis of a subject suffering from the AML and/or for prognosis of survival time of the subject, and a use of a miR-31 primary/precursor miRNA (pri/pre-miR-31) and/or a miR-31 mature miRNA (miR-31-5p) in preparation of a drug for treatment of the AML. Introduction of the miR-31-5p into cells by means of gene transduction can induce cell death of bone marrow AML cells and AML leukemic stem cells (AML-LSCs) and enhance the cytotoxicity of cytosine arabinoside as a chemotherapeutic drug, and expression of the miR-31-5p can inhibit the growth of the AML cells and the AML-LSCs, and prolong the lifetime of animals. The present disclosure provides a novel method for AML diagnosis and prognostic assessment, and further provides a gene therapeutic drug for the AML. La présente divulgation concerne u